

David E Gyorki Mbbs,, Fracs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3911358/publications.pdf>

Version: 2024-02-01

89
papers

4,587
citations

236925

25
h-index

106344

65
g-index

90
all docs

90
docs citations

90
times ranked

8879
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. <i>Nature Medicine</i> , 2009, 15, 907-913.	30.7	1,261
2	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018, 24, 986-993.	30.7	689
3	Tissue-resident memory CD8+ T cells promote melanoma immune equilibrium in skin. <i>Nature</i> , 2019, 565, 366-371.	27.8	266
4	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017, 127, 929-941.	8.2	251
5	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	1.6	190
6	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
7	Desmoplastic Melanoma: A Pathologically and Clinically Distinct Form of Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2005, 12, 207-213.	1.5	140
8	Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. <i>Lancet</i> , The, 2021, 397, 387-397.	13.7	125
9	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. <i>Annals of Oncology</i> , 2019, 30, 804-814.	1.2	117
10	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	1.5	105
11	Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14. <i>Molecular and Cellular Biology</i> , 2011, 31, 4609-4622.	2.3	96
12	Sentinel Lymph Node Biopsy for Patients With Cutaneous Desmoplastic Melanoma. <i>Annals of Surgical Oncology</i> , 2003, 10, 403-407.	1.5	94
13	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	17.5	66
14	Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence. <i>Annals of Surgical Oncology</i> , 2013, 20, 2285-2289.	1.5	61
15	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. <i>Seminars in Immunology</i> , 2016, 28, 64-72.	5.6	52
16	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	3.0	51
17	Management of recurrent retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 53-59.	1.7	48
18	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 3106-3111.	1.5	47

#	ARTICLE	IF	CITATIONS
19	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT2). <i>Cancer</i> , 2021, 127, 2251-2261.	4.1	37
20	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 2541-2549.	1.5	35
21	Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2017, 39, 772-778.	2.0	33
22	Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 1544-1554.	1.5	31
23	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 637-646.	2.5	30
24	Concurrent adjuvant radiotherapy and interferon- β for resected high risk stage III melanoma – a retrospective single centre study. <i>Melanoma Research</i> , 2004, 14, 223-230.	1.2	27
25	Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool. <i>Annals of Surgical Oncology</i> , 2016, 23, 579-584.	1.5	27
26	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. <i>Cancer Research</i> , 2016, 76, 3965-3977.	0.9	26
27	A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment. <i>European Journal of Cancer</i> , 2016, 61, 122-127.	2.8	25
28	Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. <i>Journal of Surgical Oncology</i> , 2015, 111, 980-984.	1.7	24
29	The role of ^{18}F -FDG PET/CT in retroperitoneal sarcomas – A multicenter retrospective study. <i>Journal of Surgical Oncology</i> , 2021, 123, 1081-1087.	1.7	23
30	The delicate balance of melanoma immunotherapy. <i>Clinical and Translational Immunology</i> , 2013, 2, e5.	3.8	22
31	Management of pleomorphic dermal sarcoma. <i>ANZ Journal of Surgery</i> , 2020, 90, 2322-2324.	0.7	22
32	Improving the impact of didactic resident training with online spaced education. <i>ANZ Journal of Surgery</i> , 2013, 83, 477-480.	0.7	20
33	Intralesional PV10 for in-transit melanoma – A single-center experience. <i>Journal of Surgical Oncology</i> , 2016, 114, 380-384.	1.7	19
34	Management of in-transit melanoma metastases: a review. <i>ANZ Journal of Surgery</i> , 2019, 89, 647-652.	0.7	18
35	Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study. <i>The Lancet Global Health</i> , 2022, 10, e1003-e1011.	6.3	15
36	Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 122-126.	1.9	14

#	ARTICLE	IF	CITATIONS
37	Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study. ANZ Journal of Surgery, 2020, 90, 497-502.	0.7	14
38	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. Journal of the American College of Surgeons, 2021, 232, 424-431.	0.5	14
39	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1290-1298.	2.4	14
40	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2021, 28, 6882-6889.	1.5	14
41	Current management of advanced melanoma: a transformed landscape. ANZ Journal of Surgery, 2014, 84, 612-617.	0.7	13
42	Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Research, 2017, 27, 43-49.	1.2	13
43	Endoscopic management of post-cholecystectomy biliary fistula. Hpb, 2011, 13, 699-705.	0.3	12
44	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the Australian guidelines for the management of cutaneous melanoma™. Australasian Journal of Dermatology, 2017, 58, 274-277.	0.7	12
45	Ptpn2 and KLRG1 regulate the generation and function of tissue-resident memory CD8+ T cells in skin. Journal of Experimental Medicine, 2021, 218, .	8.5	12
46	Melanoma in the very elderly, management in patients 85 years of age and over. Journal of Geriatric Oncology, 2018, 9, 488-493.	1.0	11
47	Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient's Perspective. Annals of Surgical Oncology, 2019, 26, 2263-2267.	1.5	11
48	Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study. Quality of Life Research, 2020, 29, 2021-2027.	3.1	11
49	Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: A retrospective analysis. Head and Neck, 2016, 38, 1373-1379.	2.0	10
50	Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre. ANZ Journal of Surgery, 2018, 88, 1151-1157.	0.7	10
51	Cutaneous leiomyosarcoma: dermal and subcutaneous. Australasian Journal of Dermatology, 2020, 61, 243-249.	0.7	10
52	Surgical referral coordination from a first-level hospital: a prospective case study from rural Nepal. BMC Health Services Research, 2017, 17, 676.	2.2	8
53	Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 509-511.	1.3	8
54	Accumulation of CD103 ⁺ CD8 ⁺ T cells in a cutaneous melanoma micrometastasis. Clinical and Translational Immunology, 2019, 8, e1100.	3.8	8

#	ARTICLE	IF	CITATIONS
55	Diagnosis and management of cutaneous melanoma. Australian Journal of General Practice, 2020, 49, 733-739.	0.8	8
56	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13.	0.7	7
57	Characterization of the treatment-naïve immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
58	Importance of preoperative diagnosis for management of patients with suspected retroperitoneal sarcoma. ANZ Journal of Surgery, 2018, 88, 274-277.	0.7	6
59	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. Annals of Surgical Oncology, 2019, 26, 4673-4680.	1.5	6
60	Systemic therapies for unresectable locoregional melanoma: a significant area of need. Melanoma Management, 2019, 6, MMT25.	0.5	6
61	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	1.9	6
62	Generating CAR T cells from tumor-infiltrating lymphocytes. , 2021, 9, 251513552110171.	2.3	6
63	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
64	Skin colonization with beta papilloma virus drives tissue immunity and resistance to squamous cell cancer. Immunology and Cell Biology, 2020, 98, 9-11.	2.3	5
65	An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?. Melanoma Management, 2019, 6, MMT24.	0.5	4
66	ASO Author Reflections: Standardization in the Management of Retroperitoneal Sarcoma Through International Collaboration. Annals of Surgical Oncology, 2021, 28, 7889-7890.	1.5	4
67	Ectopic breast cancer in the inguinal region. Breast Journal, 2019, 25, 155-156.	1.0	3
68	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. Australasian Journal of Dermatology, 2021, 62, 168-176.	0.7	3
69	Primary mesenteric sarcomas: Collaborative experience from the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Journal of Surgical Oncology, 2021, 123, 1057-1066.	1.7	3
70	Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Australian Journal of General Practice, 2020, 49, 355-362.	0.8	3
71	Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors. Australasian Journal of Dermatology, 2022, 63, 43-52.	0.7	3
72	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Medical Journal of Australia, 2022, 217, 208-209.	1.7	3
74	Sentinel lymph node biopsy for melanoma: an important risk stratification tool. Medical Journal of Australia, 2015, 202, 79-79.	1.7	2
75	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.6	2
76	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. Australasian Journal of Dermatology, 2022, .	0.7	2
77	Management of In-Transit Melanoma: We Need Some High-Quality Data. Journal of Oncology Practice, 2018, 14, 302-303.	2.5	1
78	Characterizing high-grade serous papillary carcinoma of tunica vaginalis. Urology Case Reports, 2019, 26, 100949.	0.3	1
79	ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of Life. Annals of Surgical Oncology, 2019, 26, 651-652.	1.5	1
80	Second-line immunotherapy in patients with metastatic melanoma. Lancet Oncology, The, 2021, 22, 746-748.	10.7	1
81	Management of Retroperitoneal Sarcomas. , 2021, , 309-322.		1
82	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. Current Anesthesiology Reports, 2015, 5, 257-267.	2.0	0
83	Restricted venous access after lymph node dissection: evidence (voodoo). ANZ Journal of Surgery, 2018, 88, 131-132.	0.7	0
84	Locoregional melanoma: identifying optimal care in a rapidly changing landscape. Melanoma Management, 2019, 6, MMT22.	0.5	0
85	Malignant transformation of an ileostomy stoma scar: an unusual presentation. ANZ Journal of Surgery, 2020, 90, 1770-1772.	0.7	0
86	Extent of ulceration in cutaneous melanoma: is this biomarker ready for primetime?. British Journal of Dermatology, 2021, 184, 192-193.	1.5	0
87	Tumor reactivity of CD8 ⁺ T cells favors acquisition of dysfunctional states in human melanoma. Immunology and Cell Biology, 2021, 99, 914-916.	2.3	0
88	Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?. Annals of Surgical Oncology, 2022, .	1.5	0
89	Retroperitoneal and Mesenteric Liposarcomas. Surgical Oncology Clinics of North America, 2022, 31, 399-417.	1.5	0